TScan Therapeutics (TCRX) Gains from Investment Securities (2021 - 2025)
Historic Gains from Investment Securities for TScan Therapeutics (TCRX) over the last 4 years, with Q3 2025 value amounting to -$291000.0.
- TScan Therapeutics' Gains from Investment Securities rose 8061.29% to -$291000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 4934.18%. This contributed to the annual value of $6.1 million for FY2024, which is 130.35% down from last year.
- According to the latest figures from Q3 2025, TScan Therapeutics' Gains from Investment Securities is -$291000.0, which was up 8061.29% from -$786000.0 recorded in Q2 2025.
- In the past 5 years, TScan Therapeutics' Gains from Investment Securities registered a high of $8.5 million during Q4 2024, and its lowest value of -$1.5 million during Q3 2024.
- Over the past 4 years, TScan Therapeutics' median Gains from Investment Securities value was -$342000.0 (recorded in 2024), while the average stood at $1.6 million.
- Examining YoY changes over the last 5 years, TScan Therapeutics' Gains from Investment Securities showed a top increase of 8061.29% in 2025 and a maximum decrease of 18189.85% in 2025.
- TScan Therapeutics' Gains from Investment Securities (Quarter) stood at $3.1 million in 2021, then surged by 108.65% to $6.4 million in 2023, then soared by 31.49% to $8.5 million in 2024, then plummeted by 103.43% to -$291000.0 in 2025.
- Its Gains from Investment Securities stands at -$291000.0 for Q3 2025, versus -$786000.0 for Q2 2025 and -$1.3 million for Q1 2025.